PTH and osteoporosis: High direct cost of treatment remains one of the main drawbacks that limits the broad application of this treatment.17 As a result, it has been suggested from pharmacoeconomic studies that PTH treatment is only justified among patients with osteoporosis in the highest quartile of fracture risk.